Cover Image
市場調查報告書

miRagen Therapeutics, Inc. :產品平台分析

miRagen Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224662
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
miRagen Therapeutics, Inc. :產品平台分析 miRagen Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月31日 內容資訊: 英文 28 Pages
簡介

miRagen Therapeutics, Inc.是發現、開發心血管及肌肉疾病之治療藥的生物製藥公司。該公司將獨家microRNA (miRNA)標的療法商品化,對提升人們的健康有卓越的貢獻。

本報告提供miRagen Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

miRagen Therapeutics, Inc.的基本資料

  • miRagen Therapeutics, Inc.概要
  • 主要資訊
  • 企業資料

miRagen Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

miRagen Therapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

miRagen Therapeutics, Inc.:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

miRagen Therapeutics, Inc.:藥物簡介

  • MGN-1374
  • MGN-4220
  • MGN-4893
  • MGN-6114
  • MGN-9103
  • MRG-106
  • MRG-107
  • Oligonucleotide for Cardiovascular Disease
  • Oligonucleotide to Inhibit miR-145 for PAH

miRagen Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

miRagen Therapeutics, Inc.:最近的開發平台趨勢

miRagen Therapeutics, Inc.:暫停中的計劃

miRagen Therapeutics, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07199CDB

Summary

Global Markets Direct's, 'miRagen Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the miRagen Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of miRagen Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of miRagen Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of miRagen Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the miRagen Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate miRagen Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of miRagen Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the miRagen Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of miRagen Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of miRagen Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of miRagen Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • miRagen Therapeutics, Inc. Snapshot
    • miRagen Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • miRagen Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • miRagen Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • miRagen Therapeutics, Inc. - Pipeline Products Glance
    • miRagen Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • miRagen Therapeutics, Inc. - Drug Profiles
    • MGN-1374
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-4220
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-4893
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-6114
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-9103
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MRG-106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MRG-107
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for Cardiovascular Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide to Inhibit miR-145 for PAH
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • miRagen Therapeutics, Inc. - Pipeline Analysis
    • miRagen Therapeutics, Inc. - Pipeline Products by Target
    • miRagen Therapeutics, Inc. - Pipeline Products by Molecule Type
    • miRagen Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • miRagen Therapeutics, Inc. - Recent Pipeline Updates
  • miRagen Therapeutics, Inc. - Dormant Projects
  • miRagen Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • miRagen Therapeutics, Inc., Key Information
  • miRagen Therapeutics, Inc., Key Facts
  • miRagen Therapeutics, Inc. - Pipeline by Indication, 2015
  • miRagen Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • miRagen Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • miRagen Therapeutics, Inc. - Preclinical, 2015
  • miRagen Therapeutics, Inc. - Pipeline by Target, 2015
  • miRagen Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • miRagen Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • miRagen Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • miRagen Therapeutics, Inc. - Dormant Developmental Projects,2015

List of Figures

  • miRagen Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • miRagen Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • miRagen Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • miRagen Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top